

Table S1: Characteristics of HIV⁺ subjects enrolled per study group.

| Patient ID | Infection Stage ¹ | Viral Load (VL) ² | | Viral Set point ³ Log ₁₀ | CD4 ⁺ T cell count ² Cells/ μ l | CD4 Set point ³ Cells/ μ l | CD4<350 cells/ μ l during first year? ^{3,4} | HAART ⁵ | HLA haplotype | | | | | |
|-----------------------------------------|------------------------------|------------------------------|-------------------|---------------------------------------------------|--------------------------------------------------------------|----------------------------------------------|----------------------------------------------------------|--------------------|---------------|-----------|-------|--------|----|----|
| | | RNA copies/ml | Log ₁₀ | | | | | | HLA-A | HLA-B | HLA-C | | | |
| Primary HIV Infection (PHI) N=44 | | | | | | | | | | | | | | |
| NP01b | V | 9,532 | 4,0 | 3,6 | 590 | 587 | NO | NO | 32 | 32 | 15 | 35 | 4 | 7 |
| NP02 | V | 2,707 | 3,4 | 3,9 | 902 | 600 | NO | NO | 1 | 3 | 35 | 37 | 4 | 6 |
| NP03 | VI | 8,613 | 3,9 | 4,4 | 851 | 758 | NO | NO | 2 | 36 | 7 | 42 | 7 | 7 |
| NP04 | V | 104 | 2,0 | 2,5 | 602 | 679 | NO | NO | 31 | 68 | 44 | 51 | 5 | 14 |
| NP05 | VI | 256,051 | 5,4 | 4,8 | 797 | 943 | NO | NO | 2 | 11/24/31* | 7 | 35 | 4 | 7 |
| NP06 | VI | 13,962 | 4,1 | 4,6 | 577 | 544 | NO | NO | 2 | 23 | 38 | 58 | 7 | 12 |
| NP07 | VI | 61,045 | 4,8 | 4,4 | 595 | 508 | NO | NO | 2 | 32 | 7.3 | 4901 | 7 | 7 |
| NP08 | V | 19,522 | 4,3 | 4,2 | 525 | 442 | NO | NO | 2 | 2 | 57 | 40CXJJ | 3 | 7 |
| NP09 | V | >500,000 | >5,7 | 4,3 | 603 | 490 | NO | NO | 2 | 68 | 14 | 51 | 1 | 8 |
| NP10 | VI | 258,015 | 5,4 | 4,5 | 803 | 670 | NO | NO | 1 | 26 | 1517 | 35.3 | 4 | 7 |
| NP11 | V | 455,417 | 5,7 | 5,2 | 698 | 685 | NO | NO | 11 | 32 | 44 | 58 | 4 | 5 |
| NP12 | VI | 17,420 | 4,2 | 4,1 | 685 | 402 | NO | NO | 2 | 68 | 15 | 40 | 3 | 8 |
| NP13 | V | 21,986 | 4,3 | 3,4 | 609 | 658 | NO | NO | 31 | 31 | 8 | 48 | 4 | 7 |
| NP14 | VI | 12361 | 4,1 | 3,9 | 732 | 764 | NO | NO | 31 | 31 | 44 | 51 | 4 | 15 |
| NP15 | VI | 9018 | 4,0 | 3,5 | 587 | 410 | NO | NO | 2 | 26 | 14 | 50 | 3 | 8 |
| NP16 | VI | 149 | 2,2 | NA | 786 | 788 | NO | NO | 31 | 3/11* | 8 | 40 | 3 | 7 |
| NP17 | VI | 508085 | 5,7 | 4,7 | 851 | 585 | NO | NO | 29 | 29 | 14 | 44 | 08 | 16 |
| NP18 | VI | 67660 | 4,8 | NA | 387 | NA | NO | NO | 26 | 33 | 38 | 44 | 4 | 12 |
| NP19 | VI | 46211 | 4,7 | 4,8 | 633 | 573 | NO | NO | 11 | 68 | 35 | 48 | 4 | 8 |
| NP20 | V | 32918 | 4,5 | 4,5 | 748 | 568 | NO | NO | 29 | 29 | 40 | 44 | 3 | 3 |
| NP21 | VI | 32473 | 4,5 | 4,7 | 500 | 652 | NO | NO | 2 | 32 | 35 | 41 | 4 | 7 |
| NP22 | VI | 116129 | 5,1 | 4,8 | 671 | 477 | NO | NO | 23 | 23 | 8 | 40 | 3 | 7 |
| NP23 | VI | 64454 | 4,8 | 5,1 | 391 | 492 | NO | NO | 29 | 29 | 14 | 55 | 3 | 8 |
| P01 | VI | 743 | 2,9 | NA | 619 | NA | YES | YES | 1 | 68 | 49 | 49 | NA | NA |
| P02 | V | >500,000 | >5,7 | NA | 341 | NA | YES | YES | 2 | 2 | 41FVE | 07 | 7 | 17 |
| P03 | V | 1,315 | 3,1 | 3,5 | 504 | 424 | YES | NO | 3 | 31 | 35.2 | 35.2 | 4 | 4 |
| P04 | VI | 3,662 | 3,6 | 3,9 | 302 | 281 | YES | NO | 2 | 33 | 14 | 15 | 2 | 8 |

| | | | | | | | | | | | | | | |
|-------|-----|----------|------|------|-----|-----|-----|-----|----|----|--------|----|----|----|
| P05 | V | 145,002 | 5,2 | NA | 308 | NA | YES | YES | 24 | 29 | 44CXHZ | 18 | 7 | 12 |
| P06 | III | >500,000 | >5,7 | NA | 117 | NA | YES | YES | 24 | 26 | 8 | 55 | 3 | 7 |
| P07 | IV | >500,000 | >5,7 | NA | 259 | NA | YES | YES | 2 | 3 | 7 | 49 | 7 | 7 |
| P08b | V | >500,000 | >5,7 | 5,4 | 374 | 342 | YES | NO | 2 | 30 | 18 | 18 | NA | NA |
| P09 | V | 98,684 | 5,0 | 4,9 | 256 | 256 | YES | NO | 2 | 11 | 18 | 35 | 4 | 7 |
| P11 | VI | 242,199 | 5,4 | 5,6 | 161 | 70 | YES | NO | 29 | 33 | 14 | 44 | 8 | 16 |
| P12 | IV | >500,000 | >5,7 | >5,7 | 379 | 246 | YES | NO | 2 | 2 | 40 | 44 | 3 | 3 |
| P13 | V | >500,000 | >5,7 | 5,2 | 333 | 297 | YES | NO | 24 | 68 | 14 | 53 | 4 | 8 |
| P14 | VI | >500,000 | >5,7 | NA | 475 | NA | YES | YES | 11 | 24 | 7 | 39 | 7 | 7 |
| P15 | VI | >500,000 | >5,7 | NA | 104 | NA | YES | YES | 2 | 11 | 35 | 40 | 3 | 4 |
| P16 | VI | 199754 | 5,3 | NA | 252 | NA | YES | UNK | 24 | 68 | 14 | 53 | 4 | 8 |
| P17 | VI | 255240 | 5,4 | 5,0 | 399 | 313 | YES | UNK | 2 | 68 | 14 | 35 | 4 | 8 |
| P18 | VI | 283825 | 5,5 | NA | 282 | NA | YES | UNK | 2 | 68 | 39 | 41 | 7 | 7 |
| P19 | VI | 102297 | 5,0 | NA | 222 | NA | YES | YES | 2 | 2 | 15 | 51 | 3 | 7 |
| PHI42 | V | 1810 | 3,3 | NA | 499 | NA | UNK | UNK | 33 | 33 | 8 | 14 | 7 | 8 |
| PHI43 | VI | 318838 | 5,5 | 5,3 | 655 | 563 | UNK | UNK | 32 | 32 | 44 | 49 | 7 | 18 |
| PHI44 | V | 16926 | 4,2 | NA | 801 | NA | UNK | UNK | 2 | 23 | 44 | 57 | 4 | 6 |

Chronics (C) N=16

| | | | | | | | | | | | | | | |
|------------------|---------|---------|-----|---|-------|---|---|----|----|-------|----|--------|----|------|
| C01 | Chronic | 18,580 | 4,3 | - | 511 | - | - | NO | 1 | 3 | 7 | 37 | 7 | 7 |
| C02 | Chronic | 12,800 | 4,1 | - | 704 | - | - | NO | 2 | 36 | 7 | 42 | 7 | 7 |
| C03 ⁶ | Chronic | 1,286 | 3,1 | - | 1,071 | - | - | NO | 2 | 3 | 35 | 44 | 4 | 5 |
| C04 | Chronic | 22,060 | 4,3 | - | 293 | - | - | NO | 2 | 2 | 7 | 35 | 5 | 16 |
| C05 ⁶ | Chronic | 555 | 2,7 | - | 555 | - | - | NO | 3 | 3 | 18 | 18 | 7 | 7 |
| C06 | Chronic | 43,436 | 4,6 | - | 479 | - | - | NO | 31 | 31 | 15 | 39 | 3 | 7 |
| C07 ⁶ | Chronic | 1,288 | 3,1 | - | 431 | - | - | NO | NA | NA | NA | NA | NA | NA |
| C08 ⁶ | Chronic | 1,817 | 3,3 | - | 689 | - | - | NO | 11 | 11 | 35 | 40 | 3 | 3 |
| C09 | Chronic | 45,199 | 4,7 | - | 282 | - | - | NO | 11 | 11 | 18 | 35 | 3 | 5 |
| C10 | Chronic | 3,093 | 3,5 | - | 227 | - | - | NO | 2 | 33 | 15 | 39 | 3 | 7 |
| C11 | Chronic | 11,026 | 4,0 | - | 585 | - | - | NO | 2 | 2 | 44 | 58 | 7 | 5/8* |
| C12 | Chronic | 85,947 | 4,9 | - | 25 | - | - | NO | 11 | 24 | 35 | 51/78* | 4 | 15 |
| C14 | Chronic | 22,475 | 4,4 | - | 143 | - | - | NO | 2 | 2/25* | 35 | 55 | 3 | 4 |
| C15 | Chronic | 14,784 | 4,2 | - | 139 | - | - | NO | 26 | 26 | 44 | 57 | 5 | 7 |
| C16 | Chronic | 253,164 | 5,4 | - | 5 | - | - | NO | 31 | 31 | 39 | 47 | 7 | 15 |
| C17 | Chronic | 36,399 | 4,6 | - | 555 | - | - | NO | 2 | 3 | 44 | 51 | 4 | 7 |

Elite controllers(EC) N=11

| | | | | | | | | | | | | | | |
|------|---------|-----|------|---|-----|---|---|----|---|---|----|----|---|---|
| EC01 | Chronic | <50 | <1,7 | - | 566 | - | - | NO | * | * | 35 | 38 | 3 | 4 |
|------|---------|-----|------|---|-----|---|---|----|---|---|----|----|---|---|

| | | | | | | | | | | | | | | |
|------|---------|-----|------|---|-------|---|---|----|----|----|--------|--------|----|------|
| EC02 | Chronic | <50 | <1,7 | - | 912 | - | - | NO | 2 | 2 | 13 | 51 | 12 | 16 |
| EC03 | Chronic | <50 | <1,7 | - | 456 | - | - | NO | 11 | 11 | 55/56* | 58 | 3 | 12 |
| EC04 | Chronic | <50 | <1,7 | - | 602 | - | - | NO | 3 | 31 | 7 | 39 | 7 | 7 |
| EC05 | Chronic | <50 | <1,7 | - | 570 | - | - | NO | 2 | 24 | 7 | 40 | 3 | 3 |
| EC06 | Chronic | <50 | <1,7 | - | 817 | - | - | NO | 33 | 66 | 14 | 42 | 8 | 17 |
| EC07 | Chronic | <50 | <1,7 | - | 389 | - | - | NO | 1 | 1 | 27 | 57 | 4 | 6 |
| EC08 | Chronic | <50 | <1,7 | - | 595 | - | - | NO | 33 | 68 | 40CXJJ | 52 | NA | NA |
| EC09 | Chronic | <50 | <1,7 | - | 612 | - | - | NO | 01 | 02 | 57 | 40CXJJ | NA | NA |
| EC10 | Chronic | <50 | <1,7 | - | 562 | - | - | NO | 25 | 32 | 44 | 58 | 7 | 5/8* |
| EC12 | Chronic | <50 | <1,7 | - | 1,261 | - | - | NO | 2 | 2 | 26 | 44 | 2 | 4 |

¹ PHI subjects were stratified according to Fiebig stages (Fiebig et al. 2003 AIDS, 17:1871-9). ² For PHI subjects, data correspond to baseline samples. For Chronic and EC subjects, data correspond to samples obtained at enrollment. ³ Only applicable to PHI subjects. ⁴ States if CD4⁺ T-cell count dropped below 350 cells/ μ l at any time during the first year post-infection. ⁵ Regarding PHI subjects, data illustrates if the subjects started HAART during the first year post-infection. For Chronic and ECs, data represents if subjects ever received HAART. ⁶ Subjects considered "Viremic Controllers" *: Unable to resolve with current protocol. NA: Data not available. UNK: Data is unknown because time since enrollment was less than one year at the time of manuscript submission.